Existing Bitter Medicines for Fighting 2019-nCoV-associated Infectious Diseases
Overview
Affiliations
The sudden outbreak of COVID-19 has led to more than seven thousand deaths. Unfortunately, there are no specific drugs available to cure this disease. Type 2 taste receptors (TAS2Rs) may play an important role in host defense mechanisms. Based on the idea of host-directed therapy (HDT), we performed a negative co-expression analysis using big data of 60 000 Affymetrix expression arrays and 5000 TCGA data sets to determine the functions of TAS2R10, which can be activated by numerous bitter substances. Excitingly, we found that the main functions of TAS2R10 involved controlling infectious diseases caused by bacteria, viruses, and parasites, suggesting that TAS2R10 is a key trigger of host defense pathways. To quickly guide the clinical treatment of 2019-nCoV, we searched currently available drugs that are agonists of TAS2Rs. We identified many cheap, available, and safe medicines, such as diphenidol, quinine, chloroquine, artemisinin, chlorpheniramine, yohimbine, and dextromethorphan, which may target the most common symptoms caused by 2019-nCoV. We suggest that a cocktail-like recipe of existing bitter drugs may help doctors to fight this catastrophic disease and that the general public may drink or eat bitter substances, such as coffee, tea, or bitter vegetables, to reduce the risk of infection.
Lu J, Zhou X, Zhu H, Zou M, Liu L, Li X 3 Biotech. 2025; 15(4):79.
PMID: 40071126 PMC: 11890915. DOI: 10.1007/s13205-025-04231-7.
Swertiamarin and sweroside are potential inhibitors of COVID-19 based on the silico analysis.
Wang W, Tan Y, Mao J, Xiong W Medicine (Baltimore). 2024; 103(45):e40425.
PMID: 39533611 PMC: 11556981. DOI: 10.1097/MD.0000000000040425.
Deciphering GABBR1-centered drug targets to fight viral infection with preexisting diabetes.
Li X, Zhao X, Peng L, Du H, Chen S, Chen X Acta Biochim Biophys Sin (Shanghai). 2023; 55(12):1999-2003.
PMID: 37969011 PMC: 10753374. DOI: 10.3724/abbs.2023249.
Developing drugs targeting CX3CL1 to treat heart diseases via immune/inflammatory mediation.
Zou L, Ma J, Hu G, Zhu H, Zhang L, Li X Acta Biochim Biophys Sin (Shanghai). 2023; 55(10):1672-1676.
PMID: 37580951 PMC: 10577471. DOI: 10.3724/abbs.2023157.
Potential of ATP5MG to Treat Metabolic Syndrome-Associated Cardiovascular Diseases.
Liu L, Zhou X, Chen J, Li X Front Cardiovasc Med. 2022; 9:921778.
PMID: 35935642 PMC: 9355403. DOI: 10.3389/fcvm.2022.921778.